Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Revolution Medicines, Inc. Chief Financial Officer reports a planned share sale. CFO Jack Anders disclosed the sale of 3,104 shares of common stock on 12/16/2025 at a price of $77.0904 per share. The transaction was made under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy his tax withholding obligations upon the vesting of restricted stock units after July 15, 2023.
Following this transaction, Anders beneficially owns 108,065 shares of Revolution Medicines common stock. This figure includes 175 shares acquired under the company’s Employee Stock Purchase Plan on November 30, 2025 and 42,338 restricted stock units, which represent a right to receive shares in the future subject to vesting conditions.
Revolution Medicines, Inc. (RVMD)11/25/2025, Anders exercised a stock option for 5,418 shares of common stock at an exercise price of $17 per share, then sold 5,418 shares of common stock at a price of $74 per share. The filing notes that the transaction was made under a Rule 10b5-1 trading plan adopted on December 16, 2024, which is designed to pre-arrange trades. After these transactions, Anders directly holds 110,994 shares of common stock, which includes 48,275 restricted stock units.
Revolution Medicines, Inc. (RVMD) reported insider activity by President, Chief Executive Officer and Director Mark A. Goldsmith. On 11/25/2025, he exercised a stock option to buy 60,000 shares of common stock at an exercise price of $4.09 per share, then sold 60,000 shares of common stock in a transaction under code M/S.
He also reported open market sales of 3,000 shares of common stock at $75 per share from each of two trusts. A weighted average sale price of $75.0827 was reported for one of the sales executed in multiple trades. After these transactions, he directly beneficially owned 247,863 shares of common stock (including 193,475 restricted stock units), and held additional indirect positions of 67,424 shares in each of two revocable trusts and 570,050 shares in a separate revocable living trust. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024.
Revolution Medicines (RVMD) President and CEO Mark A. Goldsmith reported an option exercise and stock sale. On 11/18/2025, he exercised a stock option for 20,000 shares of common stock at an exercise price of $4.09 per share, then sold 20,000 shares of common stock in open market transactions at a weighted average price of $70.3793 per share.
After these transactions, he directly beneficially owned 247,863 shares of common stock, which includes 193,475 restricted stock unitsRule 10b5-1 trading plan adopted on December 19, 2024, indicating the trades were pre-arranged under that plan.
Revolution Medicines, Inc. (RVMD) reported an insider equity transaction by its General Counsel, who is an officer of the company. On 11/18/2025, the officer exercised a stock option for 13,388 shares of common stock at an exercise price of $42.45 per share, then sold 13,388 shares of common stock on the same date at a weighted average price of $70.138 per share. After these transactions, the officer beneficially owned 50,425 shares of common stock, which includes 43,910 restricted stock units. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025.
Revolution Medicines (RVMD) reported an insider transaction on a Form 4. CFO Jack Anders exercised 10,000 stock options at $17 and sold 10,000 common shares at $64 on November 11, 2025 pursuant to a Rule 10b5-1 plan adopted on December 16, 2024.
After these transactions, Anders beneficially owned 110,994 shares, which include 48,275 restricted stock units. The option exercised related to an award with a $17 exercise price (exercisable from 02/12/2024 to 02/11/2030), with 5,418 derivative securities remaining beneficially owned.
Revolution Medicines (RVMD) — Form 4 insider activity: President and CEO Mark A. Goldsmith reported option exercises and share sales on 11/07/2025 pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024. He exercised options for 26,479 shares at $1.12 and 3,521 shares at $4.09, then sold 30,000 shares at a weighted average price of $60.3102 (trades ranged from $60.00 to $60.88).
On 11/12/2025, he recorded transfers of 50,000 shares to the Jonathan Goldsmith Revocable Trust and 50,000 shares to the Rebecca Goldsmith Revocable Trust, and reported indirect holdings in multiple family trusts. Following the transactions, direct beneficial ownership amounts were updated across entries, and his beneficial holdings include 193,475 restricted stock units.
Revolution Medicines (RVMD) reported a larger quarterly loss as it accelerates development of its RAS(ON) therapies. For the quarter ended September 30, 2025, net loss was $305.2 million or $1.61 per share, compared with $156.3 million a year ago. Operating expenses rose to $315.3 million, driven by research and development of $262.5 million and general and administrative of $52.8 million.
Liquidity remains strong with $217.4 million in cash and equivalents and $1.714 billion in marketable securities (total $1.93 billion) as of September 30, 2025, and management believes existing resources will fund operations for at least 12 months. RVMD entered a $250.0 million revenue participation agreement with Royalty Pharma, recorded as a liability of $256.5 million, with tiered royalty rates of 2.55% up to $2.0 billion in annual sales, 1.50% between $2.0–$4.0 billion, and 0.60% between $4.0–$8.0 billion. The company also established a senior secured term loan facility of up to $750.0 million, contingent on future regulatory and commercial milestones, with no amounts drawn. Shares outstanding were 189,710,951 as of September 30, 2025.
Revolution Medicines (RVMD) filed an 8-K announcing financial results for the quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition).
The information in the report and Exhibit 99.1 is furnished and not deemed filed under the Exchange Act. Listed securities include common stock (RVMD) and warrants expiring 2026 (RVMDW) on Nasdaq.
Revolution Medicines (RVMD) reported insider activity by General Counsel Jeff Cislini. On October 17, 2025, he exercised 12,000 stock options at $36.57 and sold 12,000 shares at $55 pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025.
After these transactions, he beneficially owned 50,425 shares, including 43,910 restricted stock units. The exercised option carried a $36.57 exercise price, became exercisable on June 15, 2024, and expires on June 16, 2030. Following the activity, 18,000 derivative securities remained beneficially owned.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
